Effects of Siweiyuganzi prescription on anti-peroxidation and blood lipid levels in rats with hyperlipidemia / 中国中西医结合急救杂志

ABSTRACT

Objective To observe the effects of Siweiyuganzi prescription on anti-peroxidation and blood lipid levels in experimental rats with hyperlipidemia. Methods Sixty male Sprague-Dawley (SD) rats were divided into normal control group, hyperlipidemia model group, Xuezhikang group, Siweiyuganzi prescription large, medium and small dose group according to the random number table method, with 10 rats in each group. The hyperlipidemia rat model was established by intragastric feeding with high fat emulsion everyday 10 mL·kg-1·d-1; normal saline 10 mL/kg was given to the normal control group, twice a day by intragastric feeding; 3 dosages of Siweiyuganzi suspended fluid 12.8, 6.4, 4.3 g·kg-1·d-1 intragastric administrations were given to Siweiyuganzi prescription large, medium and small dose groups respectively; Xuezhikang suspended fluid 0.3 g·kg-1·d-1 was given to Xuezhikang group intragastrically;the same volume of normal saline was given to hyperlipidemia model group. After 4 weeks, the level changes of blood lipid, serum superoxide dismutase (SOD), malonaldehyde (MDA), hydroxymethylglutaryl Coenzyme A (HMG-CoA) were observed. Results Compared to those in the normal control group, the levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), MDA, content and positive expression of HMG-CoA, alanine aminotransferase (ALT) were all higher in hyperlipidemia model group [TG (mmol/L) 6.59±0.72 vs. 4.32±0.36, TC (mmol/L) 7.10±0.25 vs. 5.98±0.40, LDL-C (mmol/L) 4.18±1.30 vs. 2.33±0.35, MDA (μmol/L) 26.05± 5.99 vs. 10.08±1.98, HMG-CoA content (ng/L) 54.60±2.90 vs. 48.73±3.09, HMG-CoA positive expression in liver tissue(57.80±12.30)% vs. (22.00±4.92)%, ALT (U/L) 106.83±15.75 vs. 81.97±13.18]; SOD and high-density lipoprotein cholesterol (HDL-C) in hyperlipidemia model group were significantly decreased [SOD (kU/L) 295.47±37.51 vs. 345.13±19.76, HDL-C (mmol/L) 2.32±0.49 vs. 4.84±0.45, both P < 0.05]. Compared with the hyperlipidemia model group, the TG, TC, LDL-C, MDA, contents and positive expression of HMG-CoA in each group were significantly reduced, and the SOD and HDL-C were obviously increased, and the changes in the Siweiyuganzi high dose group were more significant than those of the Siweiyuganzi middle-and low-dose groups [TG (mmol/L) 4.70±0.46 vs. 5.40±0.31, 5.70±0.41, TC (mmol/L) 5.80±0.23 vs. 6.14±0.20, 6.56±0.32, LDL-C (mmol/L) 2.56±0.45 vs. 2.93±0.33, 3.28±0.32, HDL-C (mmol/L) 4.58±0.28 vs. 3.89±0.30, 3.59±0.08, SOD (kU/L) 381.45±20.68 vs. 360.60±30.16, 325.49±32.13, MDA (μmol/L) 16.98±5.39 vs. 17.89±5.37, 21.03±6.01, HMG-CoA content (ng/L) 50.58±0.77 vs. 52.16±0.66, 52.90±0.91, HMG-CoA positive expression in liver tissue (27.90±6.03)% vs. (32.20±7.00)%, (43.00±8.39)%, all P < 0.05]. In the normal control group, there were positive cells scattered in the central vein area and loosely distributed around the portal area in the rat liver; in the hyperlipidemia model group, the positive cells were increased in the central vein area and the cells in relatively great number were seen around the portal area. While the positive cells in Xuezhikang group and in the high, medium and low dose Siweiyuganzi groups were decreased. Conclusion Siweiyuganzi prescription can regulate the levels of blood lipids, prevent and treat the lipid peroxidation caused by hyperlipidemia, and inhibit excessive expression of HMG-CoA in experimental rats with hyperlipidemia.